



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2098887 C 2003/10/28

(11)(21) **2 098 887**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(22) Date de dépôt/Filing Date: 1993/06/21

(41) Mise à la disp. pub./Open to Public Insp.: 1993/12/23

(45) Date de délivrance/Issue Date: 2003/10/28

(30) Priorité/Priority: 1992/06/22 (07/902,306) US

(51) Cl.Int.⁵/Int.Cl.⁵ C07H 13/02, C07H 15/04, C07H 23/00,
C07H 17/00

(72) Inventeurs/Inventors:
CHOU, TA-SEN, US;
JONES, CHARLES D., US;
MABRY, THOMAS E., US

(73) Propriétaire/Owner:
ELI LILLY AND COMPANY, US

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : METHODE DE PREPARATION DE DERIVES 1-HALO-2-DESOXY-2,2-DIFLUORO-D-
RIBOFURANOSYLIQUES ENRICHIS EN ANOMERE ALPHA

(54) Title: PROCESS FOR PREPARING ALPHA-ANOMER ENRICHED 1-HALO-2-DEOXY-2,2-DIFLUORO-D-
RIBOFURANOSYL DERIVATIVES

(57) Abrégé/Abstract:

A stereoselective process for preparing an alpha-anomer enriched 1- α -halo-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives involving contacting a 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1- β -sulfonate with a halide source in an inert solvent.

Abstract

5 A stereoselective process for preparing an alpha-anomer enriched 1- α -halo-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives involving contacting a 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1- β -sulfonate with a halide source in an inert solvent.

PROCESS FOR PREPARING ALPHA-ANOMER ENRICHED 1-HALO-2-DEOXY-
2,2-DIFLUORO-D-RIBOFURANOSYL DERIVATIVES

5 This invention pertains to a process for making
alpha-anomer enriched 3,5-hydroxy protected-1-halo-2-deoxy-
2,2-difluoro-D-ribofuranosyl derivatives for use as
intermediates in the preparation of anti-neoplastic and/or
anti-viral agents.


10 Fluorine substitution has been investigated
extensively in drug research and biochemistry as a means of
enhancing the biological activity and increasing the chemical
or metabolic stability of nucleosides. The replacement of a
hydrogen by fluorine in a bioactive molecule is expected to
15 cause minimal steric perturbations with respect to the
molecule's mode of binding to receptors or enzymes and aid in
overcoming the chemical and enzymatic instability problems of
nucleosides. Nucleosides are typically synthesized by
coupling a ribofuranosyl derivative with a purine or
20 pyrimidine nucleobase. Synthetic reactions leading to many
nucleosides involve stereochemical inversion of the
ribofuranosyl configuration at the anomeric position. When
applied to making alpha-anomer enriched starting material,
this inversion provides increased amounts of biologically
25 important beta-anomer nucleosides. Dexoydifluororibo-
furanosyl derivatives are used to prepare
deoxydifluoronucleosides. However, because the
dexoydifluororibofuranosyl derivatives exist primarily as
anomeric mixtures, anomeric mixtures of
30 deoxydifluoronucleoside products result from such coupling
reactions.

35 There continues to be a need for a stereoselective
process for preparing alpha-anomer enriched 2-deoxy-2,2-
difluoro-D-ribofuranosyl-1-halo derivatives for use as
intermediates in coupling reactions to stereoselectively make
beta-anomer nucleosides.

Accordingly, one object of the present invention is to provide a stereoselective process for preparing alpha-anomer enriched 3,5-hydroxy protected-1-halo-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives.

5 Another object of the present invention is to provide a stereoselective process for preparing alpha-anomer enriched 3,5-hydroxy protected-1-halo-2-deoxy-2,2-difluoro-D-ribofuranosyl derivatives in high yields.

10 According to the present invention there is provided a stereoselective process for preparing an alpha-anomer enriched ribofuranosyl derivative of the formula



15 wherein each X is independently selected from hydroxy protecting groups and Y is halo; comprising contacting a 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1- β -sulfonate with a halide source in an inert solvent.

20 Throughout this document, all temperatures are in degrees Celsius, all proportions, percentages and the like, are in weight units and all mixtures are in volume units, except where otherwise indicated. Anomeric mixtures are expressed as a weight/weight ratio or as a percent. The term "lactol" alone or in combination refers to 2-deoxy-2,2-

25 difluoro-D-ribofuranose. The terms "halo" or "halide" alone or in combination refer to chloro, iodo, fluoro and bromo or their anionic form, respectively. The term "alkyl" alone or in combination refers to straight, cyclic and branched chain aliphatic hydrocarbon groups which preferably contain up to 7

30 carbon atoms, such as, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl groups and the like or substituted straight, cyclic and branched chain

aliphatic hydrocarbons such as chloroethane, 1,2-dichloroethane and the like. The term "alkoxy" alone or in combination refers to compounds of the general formula RO; wherein R is an alkyl as defined above. The term "aryl" alone or in combination refers to carbocyclic or heterocyclic groups such as phenyl, naphthyl, thienyl and substituted derivatives thereof. The term "aromatic" alone or in combination refers to benzene-like structures containing $(4n + 2)$ delocalized π electrons. The term "sulfonate" alone or in combination refers to compounds of the general formula BSO_3 , wherein B is a substituted or unsubstituted alkyl or substituted or unsubstituted aryl as defined above. The term "substituted" alone or in combination refers to the replacement of hydrogen or a common moiety by one or more of the groups selected from cyano, halo, carboalkoxy, aryl, nitro, alkoxy, alkyl, halo alkyl, and dialkyl amino. The phrase "anomer enriched" alone or in combination refers to an anomeric mixture wherein the ratio of a specified anomer is greater than 1:1 and includes a substantially pure anomer.

In accordance with the present process 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1- β -sulfonate is contacted with a halide source in an inert solvent to prepare a compound of formula I.

The preparation of 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1- β -sulfonate starting materials is described in U.S. Patent 4,526,988.

Suitable halide sources useful in the present process may be selected from the group consisting of tetraalkylammonium halides, trialkylammonium halides, lithium halides, cesium halides, sodium halides and potassium halides; preferred are tetraalkylammonium halides such as tetrabutylammonium iodide and tetrabutylammonium bromide, tetramethylammonium bromide, tetramethylammonium chloride, tetramethylammonium (fluoride, 2-hydrate), tetraethylammonium bromide, tetraethylammonium chloride, tetraethylammonium

(fluoride, 2-hydrate), and trialkylammonium halides such as triethylamine hydrochloride, triethylamine hydrobromide, triethylamine hydroiodide, tricaprylmethylammonium chloride; and pyridine hydrochloride. The halide source is employed in at least equimolar amount, relative to the amount of hydroxy protected 2-deoxy-2,2-difluoro-D-ribofuranose-1- β -sulfonate employed, and more preferably is from about 1.05 molar equivalents to about 5 molar equivalents.

The solvent may be any solvent that is inert to the reaction mixture and is preferably selected from the group consisting of acetonitrile, N,N-dimethylformamide, dioxane, aryl halides such as chlorobenzene or bromobenzene, dialkyl ethers such as dibutyl ether, esters such as ethyl acetate, ketones such as acetone or 2-butanone, alkyl halides such as dichloromethane or 1,2-dichloroethane, dimethylsulfoxide, tetrahydrofuran, N,N-dimethylpropyleneurea, N-methylpyrrolidinone, and mixtures thereof. The preferred solvent depends on the halide source selected. For example, when a tetraalkylammonium halide is used, acetonitrile preferably is employed as the solvent.

The hydroxy protecting groups (X) are known in the art and are described in Chapter 3 of Protective Groups in Organic Chemistry, McOmie Ed., Plenum Press, New York (1973), and Chapter 2 of Protective Groups in Organic Synthesis, Green, John, J. Wiley and Sons, New York (1981); preferred are ester forming groups such as formyl, acetyl, substituted acetyl, propionyl, butynyl, pivaloyl, 2-chloroacetyl, benzoyl, substituted benzoyl, phenoxycarbonyl, methoxyacetyl; carbonate derivatives such as phenoxycarbonyl, t-butoxycarbonyl ethoxycarbonyl, vinyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl and benzyloxycarbonyl; alkyl ether forming groups such as benzyl, diphenylmethyl, triphenylmethyl, t-butyl, methoxymethyl, tetrahydropyranyl, allyl, tetrahydrothienyl, 2-methoxyethoxy methyl; and silyl ether forming groups such as trialkylsilyl, trimethylsilyl, isopropyl dialkylsilyl, alkyl diisopropylsilyl,

triisopropylsilyl, t-butyldialkylsilyl and 1,1,3,3,-
tetraisopropylidisloxanyl; carbamates such as N-
phenylcarbamate and N-imidazolylcarbamate; however more
preferred are benzoyl, mono-substituted benzoyl and
disubstituted benzoyl, acetyl, pivalamido, triphenylmethyl
ethers, and silyl ether forming groups, especially t-
butyldimethylsilyl; while most preferred is benzoyl.

The temperature employed in the present process is
from about room temperature to the reflux temperature of the
mixture. The process is preferably carried out under
atmospheric pressure and is substantially complete in about 5
minutes to about 24 hours.

In another embodiment of the present process, a
small amount of catalyst is added along with the halide
source to increase the nucleophilicity of the halide source.
The catalyst may be selected from the group consisting of
crown ethers such as 18-Crown-6, 15-Crown-5, and 12-Crown-4.

The progress of the present process may be followed
using high pressure liquid chromatography (HPLC) or nuclear
magnetic resonance (NMR) spectroscopy.

The following examples illustrate specific aspects
of the present process and are not intended to limit the
scope thereof in any respect and should not be so construed.

Example 1

Preparation of alpha-anomer enriched 1- α -iodo-2-
deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoate

To 1 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-
dibenzoyl-1- β - (p-bromobenzene)sulfonate were added 80 ml of
tetrahydrofuran and 80 ml of tetrabutylammonium iodide.
After about 3.5 hours at reflux the titled compound was
formed in an alpha to beta ratio of 10:1, as determined by
proton NMR spectroscopy.

To isolate the alpha-anomer the reaction mixture was cooled and diluted with dichloromethane and water. The layers were separated and the organic layer was washed with 1N HCl, sodium carbonate, saturated sodium chloride and water then dried over magnesium sulfate. The resulting solution was concentrated to an oily residue and chromatographed (silica gel, toluene/hexanes 2:1) to give 302 mg of the titled product. The yield of the titled compound was 45 percent. FDMS 489(m+2), 361(m-127), QE 300 ¹HNMR(CDCl₃) δ=8.12(m, 4H, Ar-o), 7.72-7.4(m, 6H, Ar-m and p), 6.92(d, 1H, 1-H), 5.60(dd, 1H, 3-H), 4.91-4.62(m, 3H, 4-H and 5-H).

Example 2

Preparation of alpha-anomer enriched 1-~~α~~bromo-2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoate

To 0.39 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-β-(p-bromobenzene)sulfonate were added 0.086 g of potassium bromide and 8 ml of N,N-dimethylformamide over 0.661 g of 4 angstrom sieves. After about 16 hours at 20°C the titled compound was formed in an alpha to beta ratio of 10:1, as determined by proton NMR spectroscopy.

To isolate the alpha-anomer the reaction mixture was diluted with dichloromethane and water. The layers were separated and the organic layer was washed with 0.2 M lithium chloride and water then dried over magnesium sulfate. The resulting solution was concentrated to give 234 mg of an oily residue which was substantially the titled product. A sample of the residue was chromatographed (silica gel, toluene) to give a colored oil. FDMS 442 (m + 1); Elemental Analysis: (Calc.) C: 51.72, H: 3.43, Br: 18.11; (Actual) C: 51.93, H: 3.48, Br: 18.33. QE 300 ¹HNMR(CDCl₃) δ=8.12(m, 4H, Ar-o), 7.7-7.38(m, 6H, Ar-m and p), 6.55(d, 1H, 1-H), 5.60(dd, 1H, 3-H), 4.89-4.65(m, 3H, 4-H and 5-H).

Example 3

Preparation of alpha-anomer enriched 1- α -bromo-2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoate

5

To 7.2 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1- β - (p-bromobenzene)sulfonate were added 540 ml of tetrahydrofuran and 3.65 g of tetrabutylammonium bromide. After about 2 hours at reflux the titled compound ,
10 was formed in an alpha to beta ratio of 9:1, as determined by proton NMR spectroscopy.

To isolate the alpha-anomer the reaction mixture was diluted with dichloromethane and water. The layers were separated and the organic layer was washed with 1N HCl,
15 sodium carbonate, saturated sodium chloride and water then dried over magnesium sulfate. The resulting solution was concentrated to an oily residue and chromatographed (silica gel, toluene/hexanes 2:1) to give 4.35 g of a slightly colored oil. The yield of the titled compound was 87
20 percent. FDMS 442(m + 1); Elemental Analysis: (Calc.) C: 51.72, H: 3.43, Br: 18.11; (Actual) C: 52.79, H: 3.53, Br: 18.57.

Example 4

25

Preparation of alpha-anomer enriched 1- α -iodo-2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoate

To 6 g of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1- β - (p-bromobenzene)sulfonate were added 250 ml of acetonitrile and 5.56 g of tetrabutylammonium iodide. After about 22 hours at 45°C the titled compound was formed in an alpha to beta ratio of 10:1, as determined proton NMR
30 spectroscopy.

To isolate the alpha-anomer the reaction mixture was diluted with diethyl ether and water. The layers were
35

5 separated and the organic layer was washed with 1N HCl, sodium carbonate, saturated sodium chloride and water then dried over magnesium sulfate. The resulting solution was concentrated to an oily residue and chromatographed (silica gel, toluene/hexanes 2:1) to give 4.02 g of a slightly colored oil. The yield of the titled compound was 82 percent. Elemental Analysis: (Calc.) C: 46.74, H: 3.10; (Actual) C: 46.98, H: 3.22.

10 Example 5

Preparation of alpha-anomer 1- α -fluoro-2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoate


15 To 200 mg of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1- β -(p-toluene)sulfonate were added 5 ml of tetrahydrofuran and 0.376 ml of tetrabutylammonium fluoride. After about 17 hours at 50°C the titled compound was formed, as determined proton NMR spectroscopy.

20 To isolate the alpha-anomer the reaction mixture was diluted with dichloromethane and water. The layers were separated and the organic layer was washed with 1N HCl, sodium carbonate, saturated sodium chloride and water then dried over magnesium sulfate. The resulting solution was
25 concentrated to an oily residue and chromatographed (silica gel, toluene/hexanes 2:1) to give 154 mg of a yellow oil. The yield of the titled compound was 42 percent.

30 The present invention has been described in detail, including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of the present disclosure, may make modifications and/or improvements on this invention that fall within the scope and spirit of the invention as set forth in
35 the following claims.

Claims:

1. A stereoselective process for preparing a alpha-anomer enriched ribofuranosyl derivative of the formula



10 wherein each X is independently selected from hydroxy protecting groups and Y is halo; comprising contacting a 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1-b- sulfonate with a halide source in an inert solvent.

15 2. The process of Claim 1 wherein the halide source is selected from the group consisting of tetraalkylammonium halides, trialkylammonium halides, lithium halides, sodium halides, cesium halides and potassium halides.

3. The process of Claim 2 wherein the halide source is selected from tetrabutylammonium bromide, tetrabutylammonium iodide and tetrabutylammonium fluoride.

20 4. The process of Claim 1 wherein the amount of halide source is about 1 molar equivalent to about 5 molar equivalents.

25 5. The process of Claim 1 wherein the solvent is selected from the group consisting of acetonitrile, dimethylformamide, tetrahydrofuran, N,N'-dimethylpropylene-urea, dichloromethane, and mixtures thereof.

6. The process of Claim 1 comprising adding a catalyst selected from crown ethers.